Phase 2 Study of TLK286 in Metastatic Breast Cancer
NCT00035841
·
clinicaltrials.gov ↗
PHASE2
Phase
COMPLETED
Status
60
Enrollment
INDUSTRY
Sponsor class
Conditions
Breast Neoplasms
Interventions
DRUG:
TLK286
Sponsor
Telik